# Imdelltra (tarlatamab-dlle) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tarlatamab-dlle

> The FDA approved Imdelltra (tarlatamab-dlle), sponsored by AMGEN INC (AMGN), on May 16, 2024 for to treat extensive stage small cell lung cancer.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Imdelltra (tarlatamab-dlle) FDA approved?

Yes. The FDA approved Imdelltra (tarlatamab-dlle), sponsored by AMGEN INC (AMGN), on May 16, 2024 for to treat extensive stage small cell lung cancer. FDA novel drug approvals: "Imdelltra | tarlatamab-dlle | 5/16/2024 | To treat extensive stage small cell lung cancerDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/tarlatamab-dlle)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/tarlatamab-dlle#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Imdelltra (tarlatamab-dlle) |
| Codes |  |
| Sponsor | AMGEN INC (AMGN) https://sec-api.dev/companies/amgn/catalysts |
| Indications | To treat extensive stage small cell lung cancer |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### May 16, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat extensive stage small cell lung cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Imdelltra | tarlatamab-dlle | 5/16/2024 | To treat extensive stage small cell lung cancerDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "BLA761344 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240516, review_priority PRIORITY; sponsor_name AMGEN INC; product IMDELLTRA (TARLATAMAB-DLLE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761344%22

### November 19, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761344 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority PRIORITY; sponsor_name AMGEN INC; product IMDELLTRA (TARLATAMAB-DLLE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761344%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tarlatamab-dlle.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Imdelltra (tarlatamab-dlle) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tarlatamab-dlle

```bibtex
@misc{secapidev_pdufa_tarlatamab_dlle_20261116,
  title        = {Imdelltra (tarlatamab-dlle) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tarlatamab-dlle}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tarlatamab_dlle_20261116","title":"Imdelltra (tarlatamab-dlle) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tarlatamab-dlle","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
